Table 4.
Open in new tab

Frequency of gene alterations in TNBC by PD-L1 status using DAKO 22C3 PD-L1 IHC assay.

GenePDL1+ (N = 71)PDL1− (N = 71)P value, corrected
TP5366 (93%)56 (79%).8394407
MYC24 (34%)22 (31%)1
RAD2118 (25%)18 (25%)1
PIK3CA19 (27%)16 (23%)1
PTEN11 (15%)18 (25%)1
RB110 (14%)11 (15%)1
CDKN2A10 (14%)7 (10%)1
FGFR19 (13%)7 (10%)1
WHSC1L18 (11%)8 (11%)1
LYN8 (11%)5 (7%)1
ZNF7037 (10%)6 (8%)1
CDKN2B7 (10%)6 (8%)1
CCNE16 (8%)6 (8%)1
CCND16 (8%)6 (8%)1
BRCA17 (10%)5 (7%)1
MCL16 (8%)6 (8%)1
NOTCH26 (8%)6 (8%)1
FGF195 (7%)6 (8%)1
FGF35 (7%)6 (8%)1
PIK3R13 (4%)8 (11%)1
FGF45 (7%)6 (8%)1
CREBBP6 (8%)4 (6%)1
KRAS3 (4%)6 (8%)1
AKT23 (4%)6 (8%)1
NF14 (6%)5 (7%)1
JAK26 (8%)3 (4%)1
FGF233 (4%)5 (7%)1
MTAP3 (4%)5 (7%)1
KDM5A4 (6%)4 (6%)1
NOTCH16 (8%)2 (3%)1
GenePDL1+ (N = 71)PDL1− (N = 71)P value, corrected
TP5366 (93%)56 (79%).8394407
MYC24 (34%)22 (31%)1
RAD2118 (25%)18 (25%)1
PIK3CA19 (27%)16 (23%)1
PTEN11 (15%)18 (25%)1
RB110 (14%)11 (15%)1
CDKN2A10 (14%)7 (10%)1
FGFR19 (13%)7 (10%)1
WHSC1L18 (11%)8 (11%)1
LYN8 (11%)5 (7%)1
ZNF7037 (10%)6 (8%)1
CDKN2B7 (10%)6 (8%)1
CCNE16 (8%)6 (8%)1
CCND16 (8%)6 (8%)1
BRCA17 (10%)5 (7%)1
MCL16 (8%)6 (8%)1
NOTCH26 (8%)6 (8%)1
FGF195 (7%)6 (8%)1
FGF35 (7%)6 (8%)1
PIK3R13 (4%)8 (11%)1
FGF45 (7%)6 (8%)1
CREBBP6 (8%)4 (6%)1
KRAS3 (4%)6 (8%)1
AKT23 (4%)6 (8%)1
NF14 (6%)5 (7%)1
JAK26 (8%)3 (4%)1
FGF233 (4%)5 (7%)1
MTAP3 (4%)5 (7%)1
KDM5A4 (6%)4 (6%)1
NOTCH16 (8%)2 (3%)1
Table 4.
Open in new tab

Frequency of gene alterations in TNBC by PD-L1 status using DAKO 22C3 PD-L1 IHC assay.

GenePDL1+ (N = 71)PDL1− (N = 71)P value, corrected
TP5366 (93%)56 (79%).8394407
MYC24 (34%)22 (31%)1
RAD2118 (25%)18 (25%)1
PIK3CA19 (27%)16 (23%)1
PTEN11 (15%)18 (25%)1
RB110 (14%)11 (15%)1
CDKN2A10 (14%)7 (10%)1
FGFR19 (13%)7 (10%)1
WHSC1L18 (11%)8 (11%)1
LYN8 (11%)5 (7%)1
ZNF7037 (10%)6 (8%)1
CDKN2B7 (10%)6 (8%)1
CCNE16 (8%)6 (8%)1
CCND16 (8%)6 (8%)1
BRCA17 (10%)5 (7%)1
MCL16 (8%)6 (8%)1
NOTCH26 (8%)6 (8%)1
FGF195 (7%)6 (8%)1
FGF35 (7%)6 (8%)1
PIK3R13 (4%)8 (11%)1
FGF45 (7%)6 (8%)1
CREBBP6 (8%)4 (6%)1
KRAS3 (4%)6 (8%)1
AKT23 (4%)6 (8%)1
NF14 (6%)5 (7%)1
JAK26 (8%)3 (4%)1
FGF233 (4%)5 (7%)1
MTAP3 (4%)5 (7%)1
KDM5A4 (6%)4 (6%)1
NOTCH16 (8%)2 (3%)1
GenePDL1+ (N = 71)PDL1− (N = 71)P value, corrected
TP5366 (93%)56 (79%).8394407
MYC24 (34%)22 (31%)1
RAD2118 (25%)18 (25%)1
PIK3CA19 (27%)16 (23%)1
PTEN11 (15%)18 (25%)1
RB110 (14%)11 (15%)1
CDKN2A10 (14%)7 (10%)1
FGFR19 (13%)7 (10%)1
WHSC1L18 (11%)8 (11%)1
LYN8 (11%)5 (7%)1
ZNF7037 (10%)6 (8%)1
CDKN2B7 (10%)6 (8%)1
CCNE16 (8%)6 (8%)1
CCND16 (8%)6 (8%)1
BRCA17 (10%)5 (7%)1
MCL16 (8%)6 (8%)1
NOTCH26 (8%)6 (8%)1
FGF195 (7%)6 (8%)1
FGF35 (7%)6 (8%)1
PIK3R13 (4%)8 (11%)1
FGF45 (7%)6 (8%)1
CREBBP6 (8%)4 (6%)1
KRAS3 (4%)6 (8%)1
AKT23 (4%)6 (8%)1
NF14 (6%)5 (7%)1
JAK26 (8%)3 (4%)1
FGF233 (4%)5 (7%)1
MTAP3 (4%)5 (7%)1
KDM5A4 (6%)4 (6%)1
NOTCH16 (8%)2 (3%)1
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close